How to continue Strattera after moving to

If you’re considering treatment for ADHD and wondering whether you can access non-stimulant medications like Strattera through telehealth, you’re not alone. Millions of Americans are now turning to virtual care for mental health support—and the good news is that yes, you absolutely can get ADHD non-stimulant medications prescribed through telehealth in most cases.

Unlike stimulant medications such as Adderall or Ritalin, non-stimulant ADHD medications aren’t classified as controlled substances by the DEA, which means they face far fewer regulatory hurdles when it comes to telehealth prescribing. This guide will walk you through everything you need to know about accessing non-stimulant ADHD treatment online, including current regulations, state-specific rules, and what to expect during your virtual visit.

Understanding Non-Stimulant ADHD Medications

What Makes Non-Stimulants Different?

Non-stimulant medications like Strattera (atomoxetine), Qelbree, Intuniv, and Kapvay offer an alternative approach to ADHD management. The most important distinction: these medications are not DEA-controlled substances. This means:

• No federal restrictions on telehealth prescribing
• Longer prescription supplies (often 90 days vs. 30 days for stimulants)
• Multiple refills allowed without new prescriptions
• No abuse potential or dependency risk
• Lower regulatory scrutiny for both providers and patients

Strattera, in particular, is frequently prescribed via telehealth because it’s effective for many patients and doesn’t carry the same regulatory complexity as stimulants. While it may take 4-6 weeks to reach full effectiveness (compared to same-day results with stimulants), many people find it an excellent option, especially those with:

• History of substance use concerns
• Anxiety disorders alongside ADHD
• High blood pressure or heart conditions that preclude stimulant use
• Preference for non-habit-forming medication
• Need for stable, continuous ADHD symptom management

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules: Where Things Stand in Late 2025

The DEA Telehealth Extension

As of December 2025, the DEA’s pandemic-era telehealth prescribing flexibilities remain in effect—but primarily for controlled substances (Schedules II-V). The current ‘Third Temporary Extension’ runs through December 31, 2025, allowing providers to prescribe controlled ADHD medications like Adderall via telehealth without a prior in-person examination.

Here’s what’s crucial to understand: For non-stimulant ADHD medications like Strattera, these federal restrictions never applied in the first place. The Ryan Haight Act of 2008—which normally requires an in-person medical evaluation before prescribing controlled substances online—specifically exempts non-controlled medications.

What This Means for You

If you’re seeking non-stimulant ADHD medication through telehealth:

✅ No federal requirement for an in-person visit
✅ Standard telehealth evaluation is sufficient to start treatment
✅ Licensed providers can prescribe via video visit in all 50 states (subject to state licensing)
✅ Electronic prescriptions can be sent directly to your pharmacy

The regulatory uncertainty surrounding stimulant telehealth prescribing (with the current extension expiring at year’s end) doesn’t affect non-stimulant medications. Even if federal telehealth rules for controlled substances change in 2026, Strattera and similar non-stimulants will remain accessible through virtual care.

State-by-State Telehealth Rules for ADHD Treatment

While federal law allows telehealth prescribing of non-stimulant ADHD medications nationwide, individual states have their own telehealth regulations. Here’s what you need to know about key states:

California: Telehealth-Friendly with Clear Guidelines

California permits telehealth for ADHD treatment with no mandatory in-person visit requirement for non-controlled medications. Providers must be California-licensed and establish a proper patient-provider relationship via audio-visual technology. The state has been working on AB 1503 to further clarify that telehealth examinations satisfy prescription requirements, though it’s still pending as of late 2025.

Key points:

• No in-person exam required for Strattera or other non-stimulants
• PDMP checks recommended but not legally required for non-controlled drugs
• Nurse practitioners have independent prescribing authority after meeting experience requirements

New York: Stricter for Controlled Substances Only

New York implemented new rules in May 2025 requiring an initial in-person evaluation before prescribing controlled substances via telehealth—but this doesn’t apply to non-stimulant ADHD medications.

Key points:

• Non-controlled medications (including Strattera) can be prescribed via telehealth without in-person visit
• NPs have independent practice authority
• PDMP checks required for all controlled substances but not mandatory for Strattera

Florida: Psychiatric Exception Matters

Florida generally prohibits telehealth prescribing of Schedule II stimulants—unless they’re prescribed for a psychiatric condition. Since ADHD qualifies as a psychiatric disorder, stimulant prescriptions are allowed via telehealth under this exception. For non-stimulants, there are no special restrictions.

Key points:

• Telehealth allowed for ADHD treatment (both stimulants and non-stimulants)
• No in-person requirement for non-controlled medications
• PDMP check required for every controlled substance prescription
• NP/PA require collaborative physician agreement

Texas: Mental Health Telehealth Supported

Texas is generally telehealth-friendly for mental health services. There’s no blanket in-person requirement for ADHD treatment. However, Texas does have unique restrictions on who can prescribe certain medications.

Key points:

• Telehealth fully allowed for ADHD care
• No in-person requirement for Strattera or non-stimulants
• NPs/PAs cannot prescribe Schedule II stimulants in outpatient settings (hospital/hospice only)
• Physicians can prescribe all ADHD medications via telehealth

Alabama: Among the Strictest States

Alabama requires an in-person visit within 12 months for ongoing telehealth treatment—except for mental health services. Since ADHD is classified as a psychiatric condition, this annual in-person requirement may not apply.

Key points:

• Mental health exemption likely covers ADHD telehealth treatment
• PDMP check required before every controlled substance prescription
• NP/PA can prescribe with special credentials and collaborative agreement
• Considered one of the more restrictive telehealth states

New Hampshire: Recently Relaxed Rules

New Hampshire made significant changes in August 2025 with SB 252, removing the prior in-person requirement for telehealth prescribing of controlled substances. Now only an annual follow-up evaluation is required (which can be conducted via telehealth).

Key points:

• No initial in-person visit required
• Annual evaluation required for controlled substance prescribing (can be virtual)
• PDMP check required for each controlled substance prescription
• NPs have full independent prescribing authority

Who Can Prescribe ADHD Medications via Telehealth?

Physicians (MD/DO)

In all states, licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they:

• Hold an active medical license in the patient’s state
• Have DEA registration (for controlled substances)
• Follow applicable state telehealth laws
• Maintain appropriate standard of care

Nurse Practitioners (NPs)

NP prescribing authority varies significantly by state:

Full Independent Authority States (including New York, California, Illinois, New Hampshire):

• NPs can prescribe all ADHD medications independently
• No physician oversight required after meeting experience requirements
• Can prescribe both stimulants and non-stimulants via telehealth

Collaborative Practice States (including Florida, Pennsylvania):

• NPs require physician collaboration agreement
• Can prescribe ADHD medications with physician oversight
• Authority depends on delegation and state-specific rules

Restricted States (including Georgia, Texas):

• Georgia: NPs cannot prescribe Schedule II drugs at all
• Texas: NPs can only prescribe Schedule II in hospital/hospice settings
• Both states allow NP prescribing of non-stimulants like Strattera with collaboration

Physician Assistants (PAs)

PAs typically practice under physician supervision across all states, with prescribing authority granted through collaborative agreements. Most states allow PAs to prescribe non-stimulant ADHD medications, though Schedule II stimulant authority varies.

When choosing a telehealth provider like Klarity Health, you’ll be matched with an appropriately licensed and credentialed clinician in your state who has the legal authority to prescribe ADHD medications.

What to Expect During Your Telehealth ADHD Evaluation

Comprehensive Assessment Required

Contrary to what some might think, legitimate telehealth ADHD evaluations are thorough and follow the same diagnostic criteria as in-person visits. Expect your provider to:

1. Conduct a detailed clinical interview covering:

• Current symptoms and their impact on work, school, and relationships
• Symptom history (ADHD symptoms must be present since childhood)
• Previous diagnoses or treatments
• Medical history and current medications
• Mental health history
• Family history of ADHD or related conditions

1. Use standardized assessment tools such as:

• DSM-5 diagnostic criteria questionnaires
• ADHD rating scales (self-report and possibly observer-report)
• Symptom severity assessments

1. Review supporting documentation:

• Previous medical records (if available)
• School records or work evaluations showing long-standing attention difficulties
• Input from family members or partners (especially helpful for adults diagnosed later in life)

1. Screen for other conditions that might mimic or co-exist with ADHD:

• Anxiety and depression
• Sleep disorders
• Thyroid problems
• Substance use history

The Video Visit Experience

Your telehealth appointment will typically last 30-60 minutes for an initial evaluation. You’ll need:

• A private, quiet space with good internet connection
• A device with camera and microphone (smartphone, tablet, or computer)
• Valid identification
• Insurance information (if applicable)
• List of current medications and pharmacy details

The provider will observe your presentation and behavior during the video call, ask detailed questions, and may have you complete questionnaires in real-time or beforehand.

Medication Discussion and Safety Screening

If your provider determines ADHD medication is appropriate, they’ll discuss treatment options. For non-stimulant medications like Strattera, the conversation will cover:

Benefits:

• Non-habit-forming
• Continuous 24-hour symptom coverage
• Lower potential for abuse
• Can help with anxiety symptoms alongside ADHD
• No ‘wearing off’ effect like stimulants

Important safety considerations:

• Takes 4-6 weeks for full effect (unlike stimulants that work same-day)
• Requires monitoring for blood pressure and heart rate changes
• FDA warning about suicidal thoughts in youth—monitoring is critical
• Potential for liver problems (rare but requires baseline liver function awareness)
• Cannot be taken with MAOIs or if you have narrow-angle glaucoma

Your provider will also discuss:

• Starting dose and titration plan
• Expected timeline for seeing benefits
• Potential side effects
• Follow-up schedule
• What to do if side effects occur

Red Flags and When Telehealth May Not Be Appropriate

Reputable telehealth providers carefully screen patients to ensure virtual care is safe and appropriate. You may not be a good candidate for telehealth ADHD treatment if you have:

• Unstable or severe psychiatric conditions (uncontrolled bipolar disorder, active psychosis, severe depression with suicidal ideation)
• Recent history of substance abuse requiring specialized addiction treatment
• Serious cardiovascular conditions that haven’t been evaluated by a cardiologist
• Complex medical history requiring in-person physical examination
• Active crisis situations needing immediate intervention

Warning Signs of Illegitimate Services

Be cautious of telehealth services that:

• Guarantee prescriptions before evaluation
• Don’t require video visits (phone-only consultations for controlled substances)
• Skip comprehensive assessments
• Don’t check your identification or medical history
• Don’t discuss risks, alternatives, or non-medication options
• Offer to ship medications from overseas
• Don’t schedule follow-up appointments

Legitimate providers like Klarity Health prioritize thorough evaluations, patient safety, and ongoing care coordination—never just quick prescriptions.

The Strattera Prescription Process via Telehealth

How Non-Stimulants Differ from Stimulants

Because Strattera is not a DEA-controlled substance, the prescription process is more straightforward:

Typical Timeline

Week 1-2: Initial evaluation, prescription sent to pharmacy, begin medication at starting dose

Week 2-4: Provider may check in on initial tolerability and side effects

Week 4-6: Follow-up appointment to assess effectiveness and consider dose adjustment

Ongoing: Regular follow-ups (typically every 3-6 months once stable) to monitor progress, side effects, and overall ADHD management

Pharmacy and Insurance Considerations

Most pharmacies readily fill telehealth prescriptions for Strattera without issue, since it’s not a controlled substance. Your prescription will be sent electronically to the pharmacy of your choice.

Insurance coverage: Many insurance plans cover ADHD medications, including non-stimulants, when prescribed by a licensed provider. Klarity Health works with both insurance and self-pay patients, offering transparent pricing so you know costs upfront.

Generic availability: Atomoxetine (generic Strattera) is typically more affordable than brand-name, and most insurance plans prefer the generic version.

The Current Regulatory Landscape and What’s Ahead

2025 Status and 2026 Outlook

The telehealth landscape for ADHD treatment has evolved rapidly since 2020. Here’s where we stand:

Current situation (through December 31, 2025):

• Federal telehealth flexibilities for controlled substances remain in effect
• Non-stimulant medications face no federal restrictions on telehealth prescribing
• Most states have adopted permanent or extended telehealth policies
• Increased regulatory scrutiny following controversies with some telehealth startups

Looking ahead to 2026:

• DEA expected to issue either a fourth extension or new permanent rules
• Proposed ‘Special Registration’ system for telehealth prescribers under consideration
• Congressional bills (like the TREATS Act) may expand telehealth access
• States continuing to refine and clarify telehealth regulations

For non-stimulant ADHD medications, these regulatory changes are largely irrelevant. Even if federal rules for controlled substances become stricter, Strattera and similar medications will remain accessible via telehealth under standard medical practice guidelines.

Enhanced Compliance and Patient Safety Measures

Following investigations into certain telehealth companies in 2022-2023, the industry has implemented stronger safeguards:

• More thorough diagnostic evaluations using standardized tools
• Regular follow-up requirements rather than one-time consultations
• Treatment agreements for controlled substances
• Coordination with primary care providers when appropriate
• Drug screening in some cases for stimulant prescriptions
• Enhanced identity verification and medical history review

These changes benefit patients by ensuring higher quality care while maintaining the convenience of telehealth access.

Advantages of Telehealth for ADHD Treatment

Accessibility and Convenience

For many people, telehealth removes significant barriers to ADHD care:

• No geographic limitations – Access specialists even in rural areas
• Reduced wait times – Many telehealth platforms offer appointments within days vs. months for in-person psychiatrists
• Flexible scheduling – Evening and weekend appointments more readily available
• No travel required – Especially beneficial for people with transportation challenges or busy schedules
• Continuity of care – Easier to maintain regular follow-ups

Privacy and Comfort

Many patients feel more comfortable discussing mental health concerns from home rather than in a clinical setting. For individuals with social anxiety or time constraints from work/family obligations, telehealth offers a less intimidating entry point to treatment.

Cost Considerations

Klarity Health offers both insurance-accepted visits and transparent self-pay pricing, making ADHD treatment accessible regardless of insurance status. Telehealth often proves more cost-effective when considering:

• No travel expenses
• No time off work required
• Competitive pricing compared to traditional psychiatry
• Insurance coverage similar to in-person visits in most states

Tips for Successful Telehealth ADHD Treatment

Before Your Appointment

1. Prepare your medical history – List previous diagnoses, medications tried, and current symptoms
2. Gather supporting documentation – School records, prior evaluations, or work performance reviews showing attention difficulties
3. Consider observer input – Ask a family member or close friend who knows you well to complete an observer rating scale
4. Test your technology – Ensure your camera, microphone, and internet connection work properly
5. Create a private space – Find a quiet location where you can speak openly

During Your Visit

1. Be honest and thorough – Your provider can only help if they have accurate information
2. Ask questions – Clarify anything you don’t understand about diagnosis or treatment
3. Discuss your preferences – Share concerns about medications, side effects, or treatment goals
4. Take notes – Write down important instructions about medication use
5. Discuss follow-up plans – Understand when and how you’ll check in next

After Your Appointment

1. Fill your prescription promptly – Start treatment as directed
2. Track your symptoms – Keep notes on how medication affects you (benefits and side effects)
3. Set up follow-up – Schedule your next appointment before leaving the first one
4. Communicate issues early – Don’t wait for your next appointment if you have concerns
5. Consider complementary strategies – Medication works best alongside behavioral strategies, organizational tools, and lifestyle modifications

Addressing Common Concerns and Misconceptions

‘Online ADHD prescriptions are too easy to get’

Reality: Legitimate telehealth providers follow the same diagnostic standards as in-person clinicians. If anything, providers are more cautious now due to increased regulatory scrutiny. Expect a comprehensive evaluation—not a rubber-stamp prescription.

‘Non-stimulants don’t really work for ADHD’

Reality: While stimulants are considered first-line treatment for many patients, non-stimulants like Strattera can be highly effective, especially for:

• Adults who can’t take stimulants due to heart conditions
• People with anxiety disorders (Strattera doesn’t worsen anxiety like stimulants can)
• Individuals with substance use concerns
• Patients who experience intolerable stimulant side effects

Clinical studies show that about 60-70% of patients respond well to Strattera, with significant improvement in ADHD symptoms.

‘Telehealth doctors can’t prescribe controlled medications’

Partially true: Under current federal rules (through end of 2025), telehealth providers can prescribe controlled ADHD medications like stimulants. However, this is subject to change. For non-stimulants, there has never been any restriction—telehealth prescribing has always been legal for medications like Strattera.

‘My pharmacy won’t fill telehealth prescriptions’

Mostly false: The vast majority of pharmacies readily fill legitimate telehealth prescriptions. Electronic prescriptions don’t indicate whether your visit was virtual or in-person. Some pharmacies did increase scrutiny of stimulant prescriptions from certain telehealth companies in 2023, but this primarily affected a few platforms under investigation. Using established services and maintaining a relationship with one pharmacy helps avoid any issues.

How Klarity Health Supports Your ADHD Treatment Journey

Klarity Health specializes in making mental healthcare accessible and straightforward. When it comes to ADHD treatment via telehealth, here’s what sets Klarity apart:

Licensed, Credentialed Providers

Every Klarity clinician is:

• Licensed in your state
• Board-certified or board-eligible
• Experienced in ADHD diagnosis and treatment
• Properly credentialed to prescribe medications (including DEA registration when needed)

Comprehensive, Not Quick-Fix, Approach

Klarity providers conduct thorough evaluations using evidence-based diagnostic criteria. You’ll receive:

• Detailed clinical assessment
• Personalized treatment plan
• Education about medication options
• Discussion of non-medication strategies
• Regular follow-up care

Transparent Pricing and Insurance Options

Klarity accepts insurance from major carriers and also offers clear self-pay rates. You’ll know the cost upfront—no surprise bills. This flexibility means you can access care whether or not you have insurance coverage.

Convenient Scheduling and Follow-Up

With provider availability that accommodates busy schedules, Klarity makes it easier to:

• Get initial appointments quickly (often within days)
• Schedule follow-ups at times that work for you
• Maintain consistent care without long waits

Coordination and Support

Klarity can coordinate with your primary care provider if needed and provides ongoing support between appointments. If you have questions about your medication or treatment, you’re not left waiting weeks for answers.

When to Consider In-Person Care

While telehealth works well for many ADHD patients, certain situations may warrant in-person evaluation:

• Complex diagnostic uncertainty – If multiple conditions overlap and need extensive testing
• Severe co-occurring conditions – Unstable psychiatric conditions requiring crisis intervention
• Young children – Most telehealth platforms focus on teens and adults; children often benefit from in-person pediatric ADHD specialists
• Need for physical examination – If cardiovascular concerns require EKG or detailed physical assessment
• State requirements – Some states may require periodic in-person visits for long-term controlled substance prescribing

Your telehealth provider will be transparent about whether your situation is appropriate for virtual care or if they recommend an in-person specialist. Klarity’s goal is always to ensure you receive safe, effective treatment—even if that means referring you to additional resources when appropriate.

Final Thoughts: The Future of ADHD Telehealth Access

Telehealth has transformed ADHD care access over the past five years, and that transformation appears permanent for non-stimulant medications. While regulatory changes may affect stimulant prescribing in the future, medications like Strattera will continue to be safely and legally prescribed via telehealth under standard medical practice guidelines.

The key is working with reputable, licensed providers who prioritize comprehensive evaluation and ongoing patient care—not quick prescriptions. When telehealth is done right, it offers genuine advantages: accessibility, convenience, privacy, and often lower costs, all while maintaining the same clinical standards as traditional in-person care.

If you’ve been struggling with ADHD symptoms and wondering whether telehealth might be right for you, the answer is very likely yes. A thorough virtual evaluation can determine whether non-stimulant medication like Strattera could help you manage symptoms, improve focus, and enhance your daily functioning—all from the comfort of your home.

Ready to take the next step? Consider scheduling a consultation with Klarity Health to discuss your symptoms and explore whether ADHD treatment via telehealth is appropriate for you. With licensed providers, transparent pricing, and both insurance and self-pay options, Klarity makes quality ADHD care accessible when and where you need it.

References and Sources

1. Drug Enforcement Administration. ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Substances.’ Federal Register, November 2024. Reported via FierceHealthcare. https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. Sheppard Mullin. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review, August 15, 2025. https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

3. RxAgent. ‘The Telehealth Compliance Trap: How DEA’s January 2025 Proposal Creates False Hope.’ October 2025. https://www.rxagent.co/blog/telehealth-compliance-trap

4. Center for Connected Health Policy. ‘Online Prescribing State Laws.’ Accessed November 2025. https://www.cchpca.org/topic/online-prescribing/

5. Medical News Today. ‘Is Strattera a Controlled Substance?’ January 14, 2025. https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

Note: This article was verified as current as of December 17, 2025. Telehealth regulations continue to evolve. Always confirm current requirements with your healthcare provider or consult your state’s medical board for the most up-to-date information.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment